---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073326"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:27:31.430038+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC

## Summary
- Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).
- Cash and equivalents $264.8M; expects to fund operations into 2027.
- Interim LEGEND cohort data (BCG-unresponsive ~20 patients) expected by end of Sep 2024; BLA mid-2026.
- Plans to expand LEGEND with third cohort (70-100 patients) for papillary-only NMIBC, enrollment Q4 2024.
- Deprioritized cystic fibrosis program EG-i08; Paul Hastings and Wouter Joustra elected to board.

## SEC filing metadata
- accession: 0000950170-24-073326
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/0000950170-24-073326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024073326/engn-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073326
- JSON: https://secwatch.observer/filing/0000950170-24-073326.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.